Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats

por Hallakou‐Bozec, Sophie, Kergoat, Micheline, Moller, David E., Bolze, Sébastien
Publicado 2020

Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action

por Hallakou-Bozec, Sophie, Kergoat, Micheline, Fouqueray, Pascale, Bolze, Sébastien, Moller, David E.
Publicado 2021

The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells

por Vial, Guillaume, Lamarche, Frédéric, Cottet‐Rousselle, Cécile, Hallakou‐Bozec, Sophie, Borel, Anne‐Laure, Fontaine, Eric
Publicado 2021

Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration

por Detaille, D, Vial, G, Borel, A-L, Cottet-Rouselle, C, Hallakou-Bozec, S, Bolze, S, Fouqueray, P, Fontaine, E
Publicado 2016

Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity

por Theurey, Pierre, Thang, Carole, Pirags, Valdis, Mari, Andrea, Pacini, Giovanni, Bolze, Sébastien, Hallakou‐Bozec, Sophie, Fouqueray, Pascale
Publicado 2022

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes

por Hallakou‐Bozec, Sophie, Vial, Guillaume, Kergoat, Micheline, Fouqueray, Pascale, Bolze, Sébastien, Borel, Anne‐Laure, Fontaine, Eric, Moller, David E.
Publicado 2020

Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin

por Theurey, Pierre, Vial, Guillaume, Fontaine, Eric, Monternier, Pierre‐Axel, Fouqueray, Pascale, Bolze, Sébastien, Moller, David E., Hallakou‐Bozec, Sophie
Publicado 2022

Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study

por Fouqueray, Pascale, Bolze, Sebastien, Dubourg, Julie, Hallakou-Bozec, Sophie, Theurey, Pierre, Grouin, Jean-Marie, Chevalier, Clémence, Gluais-Dagorn, Pascale, Moller, David E., Cusi, Kenneth
Publicado 2021

Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity

por Jacques, Vincent, Bolze, Sébastien, Hallakou‐Bozec, Sophie, Czarnik, Anthony W., Divakaruni, Ajit S., Fouqueray, Pascale, Murphy, Anne N., Van der Ploeg, Lex H.T., DeWitt, Sheila
Publicado 2021

Therapeutic potential of deuterium‐stabilized (R)‐pioglitazone—PXL065—for X‐linked adrenoleukodystrophy

por Monternier, Pierre‐Axel, Singh, Jaspreet, Parasar, Parveen, Theurey, Pierre, DeWitt, Sheila, Jacques, Vincent, Klett, Eric, Kaur, Navtej, Nagaraja, Tavarekere N., Moller, David E., Hallakou‐Bozec, Sophie
Publicado 2022

Short‐and long‐term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome

por Lachaux, Marianne, Soulié, Matthieu, Hamzaoui, Mouad, Bailly, Anaëlle, Nicol, Lionel, Rémy‐Jouet, Isabelle, Renet, Sylvanie, Vendeville, Cathy, Gluais‐Dagorn, Pascale, Hallakou‐Bozec, Sophie, Monteil, Christelle, Richard, Vincent, Mulder, Paul
Publicado 2020

Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis

por Gluais‐Dagorn, Pascale, Foretz, Marc, Steinberg, Gregory R., Batchuluun, Battsetseg, Zawistowska‐Deniziak, Anna, Lambooij, Joost M., Guigas, Bruno, Carling, David, Monternier, Pierre‐Axel, Moller, David E., Bolze, Sebastien, Hallakou‐Bozec, Sophie
Publicado 2021